Has Tucatinib been successfully marketed and put into use in China?

Tucatinib (also known as Tucatinib) is a new HER2 targeted oral small molecule drug, mainly used to treat HER2 positive breast cancer, especially in patients with advanced stage or brain metastasis. It has been approved and put into clinical use in European and American countries, showing strong anti-tumor activity and good tolerance, becoming an important breakthrough in the treatment of HER2 positive breast cancer. However, as of now, tucatinib has not been successfully launched in mainland China, so domestic patients are temporarily unable to obtain the drug directly through formal channels.

As it has not yet been approved by the State Food and Drug Administration, tucatinib has not been included in my country's medical insurance catalog. This means that even if some patients obtain tucatinib through special channels, they must bear the full cost of their treatment out of their own pocket. In the context that the drug import and approval process has not yet been completed, many patients who want to use tucatinib can only rely on overseas purchase of drugs to meet their drug needs, which imposes a relatively heavy financial burden.

Judging from the price situation in overseas markets, the cost of the original drug tucatinib is relatively high. Taking the European market as an example, a box of 150mg84 tablets sells for more than 40,000 yuan, which is a considerable expense for ordinary families. However, there are also more economical alternatives available - for example, the generic version of tucatinib launched by a Lao pharmaceutical company, with a specification of 150 mg 60 tablets, priced at about more than 2,000 yuan per box. This kind of generic drug is basically the same as the original drug in terms of drug ingredients, so it has become a realistic choice for many patients.

Although the prices of generic drugs are affordable, patients still need to be cautious when choosing to purchase drugs overseas to ensure that the channels are regular and the quality of the drugs is guaranteed. If tucatinib can be launched in China and included in medical insurance in the future, it will greatly improve the drug accessibility and economic burden for patients with HER2-positive breast cancer. This is also a direction that many patients and doctors are looking forward to.

Reference materials:https://www.drugs.com/

xa0